Kristiina Boettiger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristiina Boettiger has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Balazs Dome
Department of Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary; National Koranyi Institute of Pulmonology, Budapest, Hungary; Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Translational Medicine, Lund University, Lund, Sweden
12 shared publications - Clemens Aigner
Department of Thoracic Surgery, Medical University of Vienna, 1090 Vienna, Austria
12 shared publications - Karin Schelch
Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria
11 shared publications - Zsolt Megyesfalvi
Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
10 shared publications - Anna Solta
Department of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
9 shared publications - Christian Lang
Medical University of Vienna 1 Department of Thoracic Surgery, Comprehensive Cancer Center Vienna, Austria
9 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (5) , 1101-1112
Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.
- 18 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (5) , 1101-1112
Open AccessSmall Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Proteomic analysis resulting from the comparison of entinostat sensitive versus resistant cell lines
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Proteomic analysis resulting from the comparison of entinostat sensitive versus resistant cell lines
- Open Access
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Proteomic analysis resulting from the comparison of SCLC cell lines showing synergistic or additive responses to entinostat and cisplatin therapy
- 17 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Proteomic analysis resulting from the comparison of SCLC cell lines showing synergistic or additive responses to entinostat and cisplatin therapy
- Open Access
- 2 July 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 495, 139129
Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells
- 2 July 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 495, 139129
Open AccessSmall Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells
- Open Access
Small Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells
Polystyrene micro-and nanoplastics (PS-MNPs) are emerging environmental pollutants with potential implications for human health. In this study, we used two different sizes of PS-MNPs (0.25 µm and 1 µm) on non-small cell lung cancer (A549, H460), small cell lung cancer (DMS53, H372), and normal lung epithelial (BEAS-2B) cells, as well as on human-derived lung organoids, to investigate the cytotoxic effects of PS particles. At lower concentrations (< 30 µg/cm 2 , equivalent to 50 µg/ml), neither PS-MPs nor PS-NPs did not interfere with cell viability or proliferation. Intracellular kinetic assays revealed that non-malignant (BEAS-2B) lung cells showed the strongest turnover of PS-NPs compared to malignant cells. Since PS-NPs exhibited more pronounced cellular effects, we focused further analyses on their impact. Furthermore, we observed significantly increased migration, prolonged S-phase arrest along with induced DNA damage, and oxidative stress in non-malignant (BEAS-2B) lung cells. Thus, our data suggest that BEAS-2B cells exhibit the highest sensitivity to PS-NPs. We also demonstrate that after PS-NP treatment, these cells displayed decreased base excision repair capacity and increased activation of survival pathways, including AKT and ERK phosphorylation. PS-NP internalization and increase of signal pathways were validated in a more physiological lung organoid setting. Altogether, our findings suggest that PS-NPs do not significantly affect the malignant behavior of cancer cells. However, they could promote tumor-like features in normal lung cells by inducing survival pathways, migration, and alterations in stress response mechanisms. Environmental Implications: This study investigates the effects of polystyrene micro-and nanoplastics (PS-MNPs) at environmentally relevant concentrations. The tested concentrations of PS-MNPs (0, 15, 30, and 60 µg/cm 2 , equivalent to 0, 25, 50, and 100 µg/ml) are commonly studied in the literature in lung cells. While these findings provide insights into cellular responses, the overall environmental impact of PS-MNPs remains limited at realistic exposure levels. Highlights: PS-MNPs are internalized into lung cells, with higher uptake in non-malignant cells. PS-NPs lead to increased migration, DNA damage, oxidative stress, and disturbed cell cycle progression. PS-NPs promote activation of survival pathways in non-malignant cells and lung organoids. Exposure of PS-NPs may cause potential implications for lung cancer development and progression.
Open AccessSmall Particles, Big Problems: Polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells
Polystyrene micro-and nanoplastics (PS-MNPs) are emerging environmental pollutants with potential implications for human health. In this study, we used two different sizes of PS-MNPs (0.25 µm and 1 µm) on non-small cell lung cancer (A549, H460), small cell lung cancer (DMS53, H372), and normal lung epithelial (BEAS-2B) cells, as well as on human-derived lung organoids, to investigate the cytotoxic effects of PS particles. At lower concentrations (< 30 µg/cm 2 , equivalent to 50 µg/ml), neither PS-MPs nor PS-NPs did not interfere with cell viability or proliferation. Intracellular kinetic assays revealed that non-malignant (BEAS-2B) lung cells showed the strongest turnover of PS-NPs compared to malignant cells. Since PS-NPs exhibited more pronounced cellular effects, we focused further analyses on their impact. Furthermore, we observed significantly increased migration, prolonged S-phase arrest along with induced DNA damage, and oxidative stress in non-malignant (BEAS-2B) lung cells. Thus, our data suggest that BEAS-2B cells exhibit the highest sensitivity to PS-NPs. We also demonstrate that after PS-NP treatment, these cells displayed decreased base excision repair capacity and increased activation of survival pathways, including AKT and ERK phosphorylation. PS-NP internalization and increase of signal pathways were validated in a more physiological lung organoid setting. Altogether, our findings suggest that PS-NPs do not significantly affect the malignant behavior of cancer cells. However, they could promote tumor-like features in normal lung cells by inducing survival pathways, migration, and alterations in stress response mechanisms. Environmental Implications: This study investigates the effects of polystyrene micro-and nanoplastics (PS-MNPs) at environmentally relevant concentrations. The tested concentrations of PS-MNPs (0, 15, 30, and 60 µg/cm 2 , equivalent to 0, 25, 50, and 100 µg/ml) are commonly studied in the literature in lung cells. While these findings provide insights into cellular responses, the overall environmental impact of PS-MNPs remains limited at realistic exposure levels. Highlights: PS-MNPs are internalized into lung cells, with higher uptake in non-malignant cells. PS-NPs lead to increased migration, DNA damage, oxidative stress, and disturbed cell cycle progression. PS-NPs promote activation of survival pathways in non-malignant cells and lung organoids. Exposure of PS-NPs may cause potential implications for lung cancer development and progression.
- Open Access
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Data from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.
- 14 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
Purpose:Acquired chemoresistance is a frequent event in small cell lung cancer (SCLC), one of the deadliest human malignancies. Histone deacetylase inhibitors (HDACi) have been shown to synergize with different chemotherapeutic agents including cisplatin. Accordingly, we aimed to investigate the dual targeting of HDAC inhibition and chemotherapy in SCLC.Experimental Design:The efficacy of HDACi and chemotherapy in SCLC was investigated both in vitro and in vivo. Synergistic drug interactions were calculated based on the HSA model (Combenefit software). Results from the proteomic analysis were confirmed via ICP-MS, cell-cycle analysis, and comet assays.Results:Single entinostat- or chemotherapy significantly reduced cell viability in human neuroendocrine SCLC cells. The combination of entinostat with either cisplatin, carboplatin, irinotecan, epirubicin, or etoposide led to strong synergy in a subset of resistant SCLC cells. Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Proteomic analysis comparing the groups of SCLC cell lines with synergistic and additive response patterns indicated alterations in cell-cycle regulation and DNA damage repair. Cell-cycle analysis revealed that cells exhibiting synergistic drug responses displayed a shift from G1 to S-phase compared with cells showing additive features upon dual treatment. Comet assays demonstrated more DNA damage and decreased base excision repair in SCLC cells more responsive to combination therapy.Conclusions:In this study, we decipher the molecular processes behind synergistic interactions between chemotherapy and HDAC inhibition. Moreover, we report novel mechanisms to overcome drug resistance in SCLC, which may be relevant to increasing therapeutic success.